Approvals come for Regeneron and Dizal, but Roche and Replimune see knockbacks.
ApexOnco Front Page
Recent articles
The first data are dribbled out, but cross-trial comparisons look uninspiring.
The company’s pivotal trial is now set to start in the second half of 2025, from year-end 2024 previously.
Dreamm-8 is heralded as marking doctors’ ability to deal better with Blenrep’s toxicities.
But toxicity could hold back Destiny-Breast06's ability to change clinical practice.
Fears that Adriatic’s statistical survival wins would be clinically marginal haven’t materialised.
Meanwhile, Lilly gets in on the next-gen KRAS action.
Gilead came out swinging in second-line lung cancer, but it might have just whiffed.